| Autor: |
Rangwala BS; Department of Medicine, Jinnah Sindh Medical University, Karachi, 75510, Pakistan., Zuhair V; Department of Medicine, Jinnah Sindh Medical University, Karachi, 75510, Pakistan., Mustafa MS; Department of Medicine, Jinnah Sindh Medical University, Karachi, 75510, Pakistan., Mussarat A; Department of Medicine, Jinnah Sindh Medical University, Karachi, 75510, Pakistan., Khan AW; Department of Medicine, Jinnah Sindh Medical University, Karachi, 75510, Pakistan., Danish F; Department of Medicine, Jinnah Sindh Medical University, Karachi, 75510, Pakistan., Fatima Zaidi SM; Department of Medicine, Dow University of Health Sciences, Karachi, 74200, Pakistan., Rehman FU; Department of Medicine, Dow University of Health Sciences, Karachi, 74200, Pakistan., Shafique MA; Department of Medicine, Jinnah Sindh Medical University, Karachi, 75510, Pakistan. |
| Abstrakt: |
Aim: Iron deficiency (ID) is associated with heart failure (HF) in a considerable proportion of patients. To improve the quality of life, lower the frequency of hospitalizations, and lower mortality rates of chronic HF patients (HF), this meta-analysis will look into the role of iron supplementation using ferric carboxymaltose (FCM). Methods & results: From inception until 1 October 2023, we conducted a thorough literature search of electronic databases for peer-reviewed publications. Around 5229 HF patients were included, of which 2691 received FCM while 2538 received placebo. Conclusion: FCM reduces HF-related hospitalizations but doesn't improve overall or cardiovascular mortality in those with HF and ID. The overall results support FCM's role in managing iron deficiency in heart failure. |
